Cancer Lett March 2025 PMID 39864539

Atovaquone and selinexor as a novel combination treatment option in acute myeloid leukemia.

Stefanie Weiss, Bernhard Zdársky, Agnieszka Witalisz-Siepracka, Sophie Edtmayer, Anja Holzer, Kerstin Heindl, Emilio Casanova, Klaus Podar, Dagmar Stoiber

Mentions

2
Peak: 2 in Mar 2025
across 2 sources since Mar 2025

Extended reach

75
potential audience

Total likes

3

Video views

75

Mentions per month

Mar 2025

All 2 dated mentions so far are from Mar 2025.

Where it's discussed

  • Bluesky1 posts
  • YouTube1 videos

AI synopsis

What people are saying

This discussion emphasizes the importance of reproducibility in scientific research, exemplified by phrases like 'Thank you for making your methods matter' and hashtags promoting open science. The tone is supportive and focuses on methodological integrity rather than detailed critique or exploration of the treatment implications, reflecting a moderate level of engagement and interest.

AgreementNeither agree nor disagree

The post expresses positive acknowledgment of the research but doesn't show strong support or disagreement, indicated by an appreciation for reproducibility.

InterestModerate interest

While the post demonstrates some curiosity about the study, it mostly reflects general support rather than in-depth engagement.

EngagementModerate engagement

There is moderate interaction with the content, highlighting the importance of reproducibility and open science, which encourages discussion.

ImpactNeutral impact

The post recognizes the significance of the method but its direct influence on the field or clinical practice appears limited to initial acknowledgment.

Abstract in brief

  • The study explores a new treatment approach for acute myeloid leukemia (AML), focusing on how three drugs—atovaquone, selinexor, and their combination—affect the STAT3 signaling pathway, which is often dysregulated in AML and linked to poor outcomes.
  • Atovaquone and selinexor independently increase the ratio of full-length STAT3 to its truncated form, which is associated with better disease outcomes, and together they synergistically kill AML cells both in the lab and in animal models.
  • The research suggests that adjusting the STAT3 ratio with these drugs could be a promising new strategy for AML treatment, potentially improving patient survival, especially through combination therapy that also reduces leukemia cell infiltration.]

Top posts

Most liked on X and Bluesky
RRID Robot
@rridrobot.bsky.social · Bluesky

RRID:Addgene_21373, was just reported to be used in "Atovaquone and selinexor as a novel combination treatment option in acute myeloid leukemia". Thank you for making your methods matter! #accelerateopenscience #reproducibility

Mar 28, 2025 · 1 like View post →

All mentions

RRID Robot
@rridrobot.bsky.social · Bluesky

RRID:Addgene_21373, was just reported to be used in "Atovaquone and selinexor as a novel combination treatment option in acute myeloid leukemia". Thank you for making your methods matter! #accelerateopenscience #reproducibility

Mar 28, 2025 · 1 like View post →